Media stories about Unilife Corp (NASDAQ:UNIS) have been trending somewhat positive recently, according to AlphaOne Sentiment Analysis. The research group, a subsidiary of Accern, identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Unilife Corp earned a news impact score of 0.14 on AlphaOne’s scale. AlphaOne also gave press coverage about the medical instruments supplier an impact score of 100 out of 100, meaning that recent news coverage is extremely likely to have an impact on the company’s share price in the near future.
Unilife Corp (NASDAQ:UNIS) traded up 0.0000% during trading on Friday, reaching $0.1591. Unilife Corp has a 12 month low of $0.09 and a 12 month high of $6.20. The firm’s 50 day moving average is $1.28 and its 200-day moving average is $2.05.
About Unilife Corp
Unilife Corp is engaged in the designing, development and manufacturing of injectable drug delivery systems. The Company has a portfolio of product platforms, including pre-filled syringes, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems, and other systems for the targeted delivery of injectable therapies.
Receive News & Ratings for Unilife Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unilife Corp and related companies with MarketBeat.com's FREE daily email newsletter.